Drug Trial Radar · NCT05175352
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jun 7, 2022
Primary completion
Oct 11, 2024
Study completion Oct 11, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Conditions
- Eosinophilic Esophagitis
Interventions
CendakimabDrug
Specified dose on specified days
CYP substratesDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics - Area under the concentration-time curve calculated from time zero to infinity (AUC0-∞)Time frame: Up to 18 Weeks
- Pharmacokinetics - Area under the concentration-time curve calculated from time zero to 12 hours postdose (AUC0-12h)Time frame: Up to 18 Weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 004
Tucson, Arizona
Local Institution - 001
Los Angeles, California
Local Institution - 022
San Diego, California
Local Institution - 016
Bristol, Connecticut
Local Institution - 002
Inverness, Florida
Local Institution - 010
Miami, Florida
Local Institution - 021
Plantation, Florida
Local Institution - 020
Gurnee, Illinois
Local Institution - 008
Iowa City, Iowa
Local Institution - 003
Albuquerque, New Mexico
Local Institution - 018
Durham, North Carolina
Local Institution - 012
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.